AGP Executive Report
Last update: 41 minutes agoObesity Treatment: A Chinese experimental weekly injection, ribupatide, helped participants lose an average 17.7% of their body weight in 11 months, a study reported. It has not been directly compared with Wegovy or Mounjaro, and phase 3 trials are underway. Newborn Care: China is building a more joined-up system for premature babies, spanning prenatal care, intensive treatment and long-term follow-up, as preterm births rise. Medical Access: China approved Eli Lilly’s oral obesity drug orforglipron, while CAR-T cancer therapy has entered the country’s basic medical insurance scheme for the first time. Research Oversight: Shanghai dismissed two researchers after a child died in a gene-editing trial, amid concerns that earlier safety warnings were not heeded. Diabetes Outreach: A Chinese medical team offered free diabetes screening, consultations and basic medicines to residents of Zanzibar’s Pemba Island, alongside advice on diet, exercise and monitoring.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.